3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
4
Unknown
3
Completed
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma Resectable
1
Melanoma
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Interventions
Docetaxel
11
Prednisone
10
Leuprolide
10
Magnetic Resonance Spectroscopy
9
bicalutamide
8
Radiotherapy
7
Abiraterone Acetate
7
Biopsy
6
gallium 68 PSMA-11
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Surveys and Questionnaires
5
Metformin
5
Goserelin
5
radium Ra 223 dichloride
4
enzalutamide
4
apalutamide
4
Specimen Handling
4
Injections
4
Androgen Antagonists
4
pembrolizumab
3
orteronel
3
cabazitaxel
3
abiraterone
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Pioglitazone
3
Paclitaxel
3
Exercise
3
Brachytherapy
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Prostatic Neoplasms
×
Electroporation
×
Clear all
NCT02430649
2020-05-27
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Withdrawn